Determination of MIC and Disk Diffusion Quality Control Guidelines for Meropenem–Vaborbactam, a Novel Carbapenem/Boronic Acid β-Lactamase Inhibitor Combination [PDF]
Meropenem–vaborbactam is a carbapenem/cyclic boronic acid β-lactamase inhibitor combination primarily active against Gram-negative bacilli, including those harboring class A serine carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC).
Castanheira, Mariana +4 more
core +1 more source
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti +6 more
wiley +1 more source
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli +7 more
doaj +1 more source
Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative <i>Klebsiella pneumoniae</i>. [PDF]
Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam.
Avison, Matthew B +3 more
core +2 more sources
Metalloids: Semi as Metals yet Full of Antimicrobial Potential
Metalloids such as boron (B), silicon (Si), germanium (Ge), arsenic (As), antimony (Sb), and tellurium (Te) bridge metals and non‐metals, displaying unique chemical versatility. Recent research highlights their diverse antimicrobial and therapeutic potentials, from natural products to synthetic organic and organometallic molcules, underscoring renewed ...
Kevin Böhm +2 more
wiley +1 more source
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections [PDF]
AbstractTwenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days.
Ryan K, Shields +10 more
openaire +2 more sources
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring [PDF]
open8noBacteremia and ventilator-associated pneumonia due to a pan-resistant Klebsiella pneumoniae strain co-producing KPC and OXA-48 carbapenemases was successfully treated in a COVID-19 critically ill patient with a combination therapy of a high-dose ...
Cojutti P. G. +7 more
core +1 more source
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov +7 more
wiley +1 more source
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae [PDF]
ABSTRACT Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam against a global collection of 991 isolates of KPC-positive
Hackel, Meredith A. +4 more
openaire +2 more sources
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati +5 more
doaj +1 more source

